CRSP - Crispr Therapeutics AG - Stock & Dividends

CRISPR Therapeutics AG is a pioneering gene editing company that leverages its cutting-edge Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform to develop innovative gene-based medicines for severe human diseases.

The company's CRISPR/Cas9 technology enables precise and directed changes to genomic DNA, allowing for the development of novel therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology, autoimmune disorders, in vivo gene editing, and type 1 diabetes.

CRISPR Therapeutics' lead product candidate, CASGEVY, is an ex vivo CRISPR/Cas9 gene-edited cell therapy designed to treat patients with transfusion-dependent beta-thalassemia, severe sickle cell disease, and other hemoglobinopathies. This therapy involves editing a patient's hematopoietic stem and progenitor cells to produce high levels of fetal hemoglobin in red blood cells, offering a potential cure for these debilitating diseases.

In addition to CASGEVY, the company is developing a range of other promising therapies, including CAR T cell therapies targeting CD19 and CD70 for oncology and autoimmune indications, as well as in vivo gene editing programs aimed at addressing cardiovascular disease by disrupting validated targets such as angiopoietin-like protein 3 and lipoprotein. Furthermore, CRISPR Therapeutics is working on VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of type 1 diabetes.

CRISPR Therapeutics has established strategic partnerships with leading biotech companies, including Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics, to accelerate the development and commercialization of its innovative therapies.

Founded in 2013, CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and is committed to harnessing the power of gene editing to transform the lives of patients suffering from severe diseases. For more information, please visit the company's website at https://www.crisprtx.com.